Previous 10 | Next 10 |
Genmab A/S (GNMSF) Q4 2019 Earnings Conference Call February 19, 2020 12:00 PM ET Company Participants Jan van de Winkel - Chief Executive Officer David Eatwell - Chief Financial Officer Anthony Pagano - American Senior Vice President, Finance & Corporate Development Confe...
The following slide deck was published by Genmab A/S in conjunction with their 2019 Q4 earnings Read more ...
Triggered by the achievement of $3B in global Darzalex (daratumumab) sales in 2019, Genmab A/S (NASDAQ: GMAB ) earns a $150M milestone payment from Johnson & Johnson (NYSE: JNJ ) unit Janssen Biotech. More news on: Genmab A/S, Johnson & Johnson, Healthcare stocks news, Stocks on ...
The following slide deck was published by Genmab A/S in conjunction with this Read more ...
The stock market and equity investors love growth. The ability of a company to grow revenues with strong momentum is typically a sign of a hot product or service in high demand that is capturing market share. Among the fastest growing companies, consideration for measures like profitability or...
Company Announcement Genmab and CureVac enter broad strategic partnership Companies to conduct joint research on first program; option for Genmab to initiate three additional programs during 5-year research term Genmab will provide CureVac with a USD 10 million upfront payment ...
Copenhagen-based Genmab A/S ( GMAB +0.1% ) inks a five-year research collaboration and license agreement with German biotech CureVac AG aimed at developing mRNA-based antibody therapies for cancer. More news on: Genmab A/S, Healthcare stocks news, Read more ...
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen’s 13F stock portfolio on a quarterly basis. It is based on Viking Global’s regulatory 13F Form filed on 11/13/2019. Please visit our Tracking Ole Andreas Halvorsen...
The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval of Johnson & Johnson (NYSE: JNJ ) unit Janssen Biotech's Darzalex (daratumumab), combined with Takeda's (NYSE: TAK ) Velcade (bortezomib), thalidomide and dexamethasone, for the tre...
The following slide deck was published by Genmab A/S in conjunction with this Read more ...
News, Short Squeeze, Breakout and More Instantly...
2024-08-01 01:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Innovative Eyewear Inc. (LUCY) rose 78.0% to $0.58749 on volume of 130,454,575 shares Ocean Power Technologies Inc. (OPTT) rose 29.6% to $0.2073 on volume of 51,927,154 shares Cosmos Health Inc. (COSM) rose 64.9% to $1.12 on volume of...
Company Announcement Positive CHMP opinion based on results from the Phase 1/2 EPCORE ® NHL-1 study FL is the second most common type of NHL and accounts for approximately 20-30 percent of all global cases If approved, epcoritamab (TEPKINLY ® ...